FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii), for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
Zymeworks Presents Preclinical Data on ZW171 at the Society for Immunotherapy of Cancer (SITC) Conference
We are pleased to present preclinical data on ZW171 in a poster presentation at the annual SITC Conference, taking place November 6-10 in Houston, TX. The poster presentation titled “Mechanistic QSP modeling and translational strategy for determining an FIH dose for ZW171, a bispecific 2+1 T-cell engager molecule targeting mesothelin and CD3” (Abstract #: 1062) […]
Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
We’re excited to share further details on our upcoming presentations at the European Organisation for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research (EORTC-NCI-AACR) Conference taking place in Barcelona on October 23-25, 2024. Oral Presentation: Title: ZW220, a NaPi2b-directed topoisomerase I inhibitor Antibody-Drug Conjugate, demonstrates compelling preclinical activity in NSCLC, ovarian and […]
Zymeworks Announces Upcoming Scientific Presentation at the Society for Immunotherapy of Cancer Annual Meeting
We are excited to announce a poster presentation highlighting preclinical data for ZW171 at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, taking place November 6-10, 2024, in Houston, Texas. Presentation Details Title: Mechanistic QSP modeling and translational strategy for determining an FIH dose for ZW171, a bispecific 2+1 T-cell engager molecule targeting […]
Zymeworks Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024
Zymeworks is pleased to announce, along with our partners Jazz Pharmaceuticals, updated data, including median progression-free survival (mPFS) and overall survival (OS) findings, from the Phase 2 trial of zanidatamab, an investigational dual HER2-targeted bispecific antibody, in combination with chemotherapy as first-line treatment for patients with HER2-expressing advanced or metastatic gastroesophageal adenocarcinoma (mGEA). Data from […]
Zymeworks Showcases New and Updated Clinical Data for Zanidatamab at ESMO 2024
Zymeworks is pleased to announce, along with our partners Jazz Pharmaceuticals, presentations on new and updated data from trials of zanidatamab at the European Society for Medical Oncology (ESMO) Congress 2024 from September 13-17, 2024, in Barcelona, Spain. New and updated data with longer follow-up, including overall survival findings, will be presented from an ongoing […]
Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock
Zymeworks Provides Corporate Update and Reports Second Quarter 2024 Financial Results
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate
Zanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract Cancer
Zymeworks is pleased to announce, along with our partners Jazz Pharmaceuticals, that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review of the Biologics License Application (BLA) for zanidatamab, the human epidermal growth factor receptor 2 (HER2)-targeted bispecific antibody, for the treatment of previously treated, unresectable, locally advanced, or metastatic HER2-positive biliary […]
